Marcel B Bally Selected Research

Drug Therapy (Chemotherapy)

10/2018	Liposomal formulations of carboplatin injected by convection-enhanced delivery increases the median survival time of F98 glioma bearing rats.
11/2017	In Vivo Validation of PAPSS1 (3'-phosphoadenosine 5'-phosphosulfate synthase 1) as a Cisplatin-sensitizing Therapeutic Target.
7/2015	3'-Phosphoadenosine 5'-phosphosulfate synthase 1 (PAPSS1) knockdown sensitizes non-small cell lung cancer cells to DNA damaging agents.
6/2014	Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer.
4/2011	Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine.
1/2007	Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects.
11/2006	Chemodosimetry of in vivo tumor liposomal drug concentration using MRI.
10/2006	Temporal targeting in cancer: combined chemotherapy and antiangiogenic therapy.
8/2006	Gene silencing in the development of personalized cancer treatment: the targets, the agents and the delivery systems.
10/2005	The formulation of lipid-based nanotechnologies for the delivery of fixed dose anticancer drug combinations.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marcel B Bally Research Topics

Disease

71	Neoplasms (Cancer) 01/2022 - 04/2002
16	Breast Neoplasms (Breast Cancer) 01/2018 - 09/2003
7	Colorectal Neoplasms (Colorectal Cancer) 02/2015 - 10/2004
6	Ovarian Neoplasms (Ovarian Cancer) 12/2018 - 06/2010
6	Carcinoma (Carcinomatosis) 12/2016 - 01/2005
5	Lung Neoplasms (Lung Cancer) 01/2021 - 03/2007
5	Prostatic Neoplasms (Prostate Cancer) 01/2021 - 05/2005
4	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022 - 01/2018
4	Glioblastoma (Glioblastoma Multiforme) 10/2018 - 03/2006
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2017 - 11/2004
4	Hypoxia (Hypoxemia) 01/2016 - 11/2004
3	Glioma (Gliomas) 10/2018 - 06/2009
3	Lymphoma (Lymphomas) 08/2017 - 11/2011
3	Hyperthermia 02/2008 - 06/2004
2	Small Cell Carcinoma 12/2018 - 01/2017
2	Hematologic Neoplasms (Hematological Malignancy) 01/2018 - 01/2013
2	Neuroblastoma 06/2017 - 01/2017
2	Disease Progression 06/2014 - 05/2011
2	Ascites 05/2011 - 02/2004
2	Weight Loss (Weight Reduction) 11/2009 - 11/2006
2	Melanoma (Melanoma, Malignant) 08/2002 - 07/2002
1	Carcinogenesis 01/2021
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2020
1	Brain Neoplasms (Brain Tumor) 10/2018
1	Starvation 11/2017
1	Adenocarcinoma of Lung 11/2017

Drug/Important Bio-Agent (IBA)

25	Pharmaceutical PreparationsIBA 01/2022 - 06/2004
19	Liposomes (Liposome)IBA 01/2022 - 08/2002
9	Doxorubicin (Adriamycin)FDA LinkGeneric 02/2013 - 09/2003
8	Proteins (Proteins, Gene)FDA Link 12/2018 - 09/2003
8	Irinotecan (Camptosar)FDA LinkGeneric 02/2015 - 10/2004
7	LipidsIBA 01/2022 - 07/2002
6	Therapeutic UsesIBA 01/2022 - 04/2004
6	PlatinumIBA 12/2017 - 02/2013
6	integrin-linked kinaseIBA 01/2015 - 05/2005
5	Small Interfering RNA (siRNA)IBA 01/2021 - 03/2006
5	Fluorouracil (Carac)FDA LinkGeneric 02/2015 - 11/2008
5	bisbenzimide ethoxide trihydrochloride (Hoechst 33342)IBA 02/2015 - 11/2004
4	Cisplatin (Platino)FDA LinkGeneric 12/2017 - 02/2008
4	Topotecan (Hycamtin)FDA LinkGeneric 06/2017 - 02/2013
4	Trastuzumab (Herceptin)FDA Link 10/2016 - 04/2004
4	QLT 0267IBA 01/2015 - 01/2006
4	liposomal doxorubicin (Doxil)FDA Link 02/2013 - 01/2005
4	Gefitinib (Iressa)FDA Link 01/2013 - 04/2004
4	Cytotoxins (Cytolysins)IBA 01/2013 - 02/2004
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2008 - 02/2004
4	Antisense OligonucleotidesIBA 03/2006 - 08/2002
3	CX 5461IBA 01/2022 - 01/2017
3	Drug CombinationsIBA 10/2021 - 04/2004
3	Carboplatin (JM8)FDA LinkGeneric 10/2018 - 01/2017
3	DNA (Deoxyribonucleic Acid)IBA 11/2017 - 11/2004
3	Biological ProductsIBA 01/2016 - 04/2002
3	Docetaxel (Taxotere)FDA Link 05/2011 - 06/2010
3	Vincristine (Oncovin)FDA LinkGeneric 04/2011 - 01/2004
3	Contrast MediaIBA 01/2007 - 06/2004
3	oblimersen (G3139)IBA 11/2004 - 07/2002
2	SolutionsIBA 01/2022 - 01/2016
2	taxaneIBA 01/2021 - 03/2014
2	ProdrugsIBA 01/2021 - 06/2010
2	AntigensIBA 01/2020 - 05/2004
2	Disulfiram (Antabuse)FDA Link 01/2018 - 01/2016
2	Clioquinol (Vioform)FDA Link 01/2018 - 12/2017
2	CopperIBA 01/2018 - 12/2017
2	Ditiocarb (Sodium Diethyldithiocarbamate)FDA Link 12/2017 - 01/2016
2	CholesterolIBA 01/2017 - 02/2008
2	Peptides (Polypeptides)IBA 12/2016 - 05/2004
2	Glucose (Dextrose)FDA LinkGeneric 01/2016 - 07/2011
2	LactonesIBA 02/2015 - 02/2008
2	LuciferasesIBA 01/2015 - 05/2011
2	Lipid NanoparticlesIBA 12/2014 - 11/2011
2	Estrogen ReceptorsIBA 06/2014 - 04/2004
2	ErbB Receptors (EGF Receptor)IBA 12/2007 - 04/2004
2	Vinorelbine (Navelbine)FDA LinkGeneric 03/2007 - 11/2004
2	ManganeseIBA 01/2007 - 11/2006
2	Antineoplastic Agents (Antineoplastics)IBA 11/2006 - 04/2002
2	SuspensionsIBA 11/2004 - 04/2004
2	OligodeoxyribonucleotidesIBA 09/2003 - 07/2002
1	Dimyristoylphosphatidylcholine (DMPC)IBA 01/2022
1	Cytarabine (Cytosar-U)FDA LinkGeneric 10/2021
1	Daunorubicin (Cerubidine)FDA LinkGeneric 10/2021
1	alvocidib (flavopiridol)IBA 10/2021
1	Androgen Receptors (Androgen Receptor)IBA 01/2021
1	CarcinogensIBA 01/2021
1	QuercetinIBA 01/2020
1	OTS964IBA 12/2019
1	Protein Kinases (Protein Kinase)IBA 12/2019
1	Histone Deacetylase InhibitorsIBA 12/2018
1	Histones (Histone)IBA 12/2018
1	quisinostatIBA 12/2018
1	Antifungal AgentsIBA 01/2018
1	LigandsIBA 12/2017
1	Oxyquinoline (8 Hydroxyquinoline)FDA Link 12/2017
1	plumbaginIBA 12/2017
1	pyrithioneIBA 12/2017
1	Biomarkers (Surrogate Marker)IBA 11/2017

Therapy/Procedure

16	Therapeutics 09/2018 - 04/2002
11	Drug Therapy (Chemotherapy) 10/2018 - 04/2002
4	Aftercare (After-Treatment) 01/2015 - 06/2004
3	Immunotherapy 06/2019 - 05/2004
3	Radiotherapy 06/2017 - 08/2006